(:ATHX)
Business Focus: N/A
Oct 23, 2023 09:31 am ET
Thinking about buying stock in XORTX Therapeutics, Tempest Therapeutics, Ginkgo Bioworks Holdings, Athersys, or Textainer Group Holdings?
NEW YORK, Oct. 23, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XRTX, TPST, DNA, ATHX, and TGH.
Oct 20, 2023 09:31 am ET
Thinking about buying stock in AGNC Investment, Lithium Americas, VinFast Auto, Athersys, or Ginkgo Bioworks Holdings?
NEW YORK, Oct. 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGNC, LAC, VFS, ATHX, and DNA.
Oct 18, 2023 09:31 am ET
Thinking about buying stock in Athersys, Mullen Automotive, Lithium Americas, Connexa Sports Technologies, or Freeline Therapeutics Holdings?
NEW YORK, Oct. 18, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATHX, MULN, LAC, CNXA, and FRLN.
Oct 16, 2023 04:52 pm ET
Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K. (“Healios”) under the acute respiratory distress syndrome (“ARDS”) global license.
Oct 13, 2023 09:31 am ET
Thinking about buying stock in Outset Medical, Tempest Therapeutics, Cassava Sciences, Rivian Automotive, or Athersys?
NEW YORK, Oct. 13, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OM, TPST, SAVA, RIVN, and ATHX.
Oct 12, 2023 09:31 am ET
Thinking about buying stock in Phio Pharmaceuticals, Barrick Gold, Clearmind Medicine, Athersys Inc, or Wheeler Real Estate Investment Trust?
NEW YORK, Oct. 12, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PHIO, GOLD, CMND, ATHX, and WHLR.
Oct 10, 2023 08:30 am ET
Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios
Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company’s ongoing Phase 3 MASTERS-2 pivotal clinical trial evaluating MultiStem® for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients is insufficiently powered to achieve the primary endpoint of mRS Shift analysis at Day 365. There we
Oct 03, 2023 04:30 pm ET
Athersys Licenses its Animal Health Assets to Ardent Animal Health
Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, and Multipotent Adult Progenitor Cell (MAPC®) technology for equine, canine, and feline health applications, announces the signing of a licensing agreement with Ardent Animal Health (Ardent). Ardent is a privately held veterinary biotechnology company developing regenerative medicine and cancer therapies for animals.
Oct 02, 2023 05:04 pm ET
Athersys Director Jane Wasman Appointed Board Chair
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces changes to its Board of Directors following the Company’s recent 2023 Annual Meeting of Stockholders. Current Director Jane Wasman, JD, has been appointed Board Chair, effective September 28, 2023. Ms. Wasman has served as a Director of the Company since November 2020, currently serving as Chair of Athersys’ Audit Committee and previously serving as Chair of its Nominations, Governance & Compliance Committee.
Sep 06, 2023 02:45 pm ET
Grant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney Transplantation
Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that Dr. Samuel Tingle, a surgeon and PhD candidate at Newcastle University in Newcastle upon Tyne, England, has received grant funding from the UK Research and Innovation’s Medical Research Council to explore the potential use of Athersys’ MultiStem cellular therapy during machine perfusion prior to kidney transplantation. Machine perfusion refers to a technology used for limiting the damaging effects of rem
Aug 17, 2023 09:30 pm ET
Athersys, Inc. Announces Pricing of $3.5 Million Public Offering
Athersys, Inc. (Nasdaq: ATHX), today announced the pricing of its “reasonable best efforts” public offering of 10,937,500 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.32 per share. The Company further agreed to issue to the investors Series A Warrants to purchase up to an aggregate of 10,937,500 shares of common stock and Series B Warrants to purchase up to an aggregate of 10,937,500 shares of common stock. The Series A and Series B Warrants will have an exercise price of $0.32 per share, will be exercisable immediately following the date of is
Aug 16, 2023 05:01 pm ET
Athersys Reports Second Quarter 2023 Financial Results and Business Highlights
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and six months ended June 30, 2023 and provided a business update.
Aug 11, 2023 08:00 am ET
Athersys Appoints Neema Mayhugh, PhD to its Board of Directors
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Neema Mayhugh, PhD to its Board of Directors. Dr. Mayhugh is an executive with more than 20 years of experience in healthcare consulting, industry, academic and hospital settings.
Jul 31, 2023 01:38 pm ET
Athersys to Host Business Update Conference Call on August 9th
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on August 9, 2023, at 4:30 p.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company’s recent clinical and operational progress and discuss timing to con
Jun 01, 2023 04:40 pm ET
Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys’ MultiStem® Following Hemorrhagic Trauma
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announces patient enrollment has begun in the third and final cohort in MATRICS-1, the Phase 2 clinical study evaluating MultiStem® in patients following resuscitation from hemorrhagic trauma. This study is being conducted at The University of Texas Health Science Center at Houston (UTHealth Houston) and Memorial Hermann-Texas Medical Center, a leading certified Level One Trauma Center, and approximately 140 patients will
May 23, 2023 08:30 am ET
Athersys Restructures Debt with Supplier
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications announced it has restructured its outstanding debt with a supplier (“the supplier”). The Company previously entered into agreements with the supplier to assist in the scale-up and manufacturing of clinical and commercial grade MultiStem® using Athersys’ bioreactor production processes.
May 18, 2023 09:58 am ET
Athersys Reports First Quarter 2023 Financial Results and Business Highlights
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced on Monday, May 15th financial results for the three months ended March 31, 2023 and provided a business update.
May 08, 2023 09:49 am ET
Athersys to Participate in Three Upcoming Conferences
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today its participation in three upcoming conferences during the month of May. Chris Temple, Vice President of Operations, will be participating in the Pharma Manufacturing World Summit and Allogeneic Cell Therapies Summit, both in Boston, Massachusetts. Dr. Sarah Busch, Vice President of Regenerative Medicine and Head of Business Development, will be attending the American Thoracic Society’s (ATS) Respiratory Innovation Summit in
May 01, 2023 08:30 am ET
Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their participation in the Cellular Therapeutics in Trauma and Critical Care’s (CTTACC) conference, “Cellular Therapies and Transfusion Medicine in Trauma and Critical Care,” from May 8-11, 2023 in Scottsdale, Arizona.
Apr 21, 2023 02:23 pm ET
Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their participation in The American Society for Neural Therapy and Repair Annual Conference from April 27-30, 2023 in Clearwater, FL.
Apr 19, 2023 04:01 pm ET
Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placement
Athersys, Inc. (Nasdaq: ATHX) today announced that it has closed its previously announced offering to sell 3,685,000 shares (the “Shares”) of the Company’s common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants to purchase 3,685,000 Shares at a purchase price per Share (and accompanying warrant) of $1.00 in a concurrent private placement (together with the registered direct offering, the “offering”). The warrants have an exercise price of $0.96 per share, are initially exercisable beginning six months following the date of issuance and expire se
Apr 18, 2023 08:00 am ET
Athersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private Placement
Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into definitive agreements for the purchase and sale of 3,685,000 shares (the “Shares”) of the Company’s common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants to purchase up to 3,685,000 Shares at a purchase price per Share (and accompanying warrant) of $1.00 in a concurrent private placement (together with the registered direct offering, the “offering”). The warrants will have an exercise price of $0.96 per share, will be initially exercisable beginning six months following the
Apr 10, 2023 03:29 pm ET
Athersys to Host Business Update Conference Call on April 20th
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on April 20, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company’s recent clinical and operational progress and discuss upcoming mile
Mar 31, 2023 06:26 pm ET
Athersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Athersys, Inc. (NASDAQ: ATHX) today announced financial results for the three and 12 months ended December 31, 2022, and provided a business update.
Mar 22, 2023 08:30 am ET
Athersys Announces Successful Type B Meeting with the FDA
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced planned amendments to its MASTERS-2 clinical trial protocol following a Type B meeting with the U.S. Food & Drug Administration (FDA). Held on March 21, 2023, the meeting addressed Athersys’ proposed modifications that seek to establish primary and secondary endpoints that it believes best reflect the full potential benefit of MultiStem treatment for patients with acute, moderate-to-severe ischemic stroke as well as the
Feb 28, 2023 08:15 am ET
Athersys Expands IP Protection with First New Patent for SIFU® Technology
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that the United States Patent and Trademark Office has granted the Company a new patent for its novel cryogenic storage system, the Secure Integrated Freezer Unit (SIFU®). This U.S. Patent No. 11,566,834, titled “Apparatus and Method for Cryostorage and Manipulation of a Plurality of Container Units,” adds to the Company’s existing IP portfolio and is an important milestone.
Feb 14, 2023 08:33 am ET
Athersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that the Company has been granted a clinical Type B meeting with the U.S. Food & Drug Administration (FDA). The Company was previously granted Regenerative Medicine Advanced Therapy (RMAT) and fast track designations for the use of MultiStem in the treatment of ischemic stroke. These designations enable sponsors to work closely with the FDA and receive its guidance on expediting advancement of designated pr
Feb 02, 2023 08:30 am ET
Athersys to Host Business Update Conference Call on February 14th
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on February 14, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert “Willie” Mays, Executive Vice President Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company’s recent clinical and operational progress, upcoming milest
Jan 30, 2023 11:20 am ET
Athersys to Participate in International Stroke Conference and BioProcess International
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its participation in two upcoming conferences, the International Stroke Conference 2023 (ISC) from February 8-10, 2023 in Houston, TX and BioProcess International US West from February 27-March 2, 2023 in San Diego, CA. Any registered attendees interested in meeting with Athersys at either conference can contact Ellen Gurley at [email protected] to set up a m
Jan 11, 2023 12:11 pm ET
Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in January
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today their participation in two January conferences, Advanced Therapies Week presented by Phacilitate from January 17-20, 2023 in Miami, FL and the 2nd Allogeneic Cell Therapies Summit Europe from January 30-February 1, 2023 in London, UK.
Jan 09, 2023 08:30 am ET
Athersys Provides MultiStem Clinical Update
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of ischemic stroke (MASTERS-2). MultiStem is a proprietary off-the-shelf stem cell product in late-stage clinical trials for acute ischemic stroke, as well as trauma and other inflammatory conditions.
Jan 05, 2023 04:33 pm ET
Athersys Appoints Joseph Nolan to Its Board of Directors
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Joseph “Joe” Nolan to its Board of Directors, effective January 4, 2023. Mr. Nolan is an experienced biotechnology and pharmaceutical executive who currently serves as Chief Executive Officer of Jaguar Gene Therapy, LLC. With this appointment, Athersys has five Directors, four of whom are independent.
Nov 15, 2022 08:00 am ET
Athersys Reports Third Quarter 2022 Financial Results and Provides Business Update
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and nine months ended September 30, 2022 and provided a business update.
Nov 11, 2022 08:30 am ET
Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital Conference and Participate in A.G.P.’s Biotech Conference
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its participation in two November conferences, the Challenges and Opportunities for Mesenchymal Stem Cells digital conference being held November 17-18, 2022 and A.G.P.’s Biotech Conference on November 30, 2022.
Nov 10, 2022 03:12 pm ET
Athersys, Inc. Announces Closing of $5.5 Million Confidentially Marketed Public Offering
Athersys, Inc. (Nasdaq: ATHX) today announced the closing of its previously announced confidentially marketed public offering with healthcare-focused U.S. institutional investors for the purchase of 5,004,545 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 10,009,090 of common stock at a combined purchase price of $1.10, resulting in gross proceeds of approximately $5.5 million before deducting placement agent fees and other offering expenses. The warrants have an exercise price of $1.10 per share, are exercisable immediately fo
Nov 10, 2022 08:55 am ET
Athersys Reschedules Third Quarter Conference Call to November 15
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it intends to file its quarterly report on Form 10-Q for the three months ended September 30, 2022 with the U.S. Securities and Exchange Commission (SEC) after market close on Monday, November 14, 2022, issue a news release reporting those financial results and recent business highlights before market open on Tuesday, November 15, 2022, and hold a conference call at 11:00 a.m. Eastern Time on Tuesday, November 15, 2022.
Nov 09, 2022 08:59 am ET
Athersys, Inc. Announces Pricing of $5.5 Million Public Offering
Athersys, Inc. (Nasdaq: ATHX) (“Athersys” or the “Company”) today announced the pricing of its previously announced "best efforts" public offering of 5,004,545 shares of common stock (or common stock equivalents) and warrants to purchase 10,009,090 shares of common stock at a combined price of $1.10 per share and accompanying warrant for aggregate gross proceeds of approximately $5.5 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $1.10 per share, will be exercisable immediately following the date of issuance and will expi
Nov 07, 2022 04:19 pm ET
Athersys, Inc. Announces Proposed Public Offering
Athersys, Inc. (Nasdaq: ATHX) (“Athersys” or the “Company”) today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase common stock, subject to market and other conditions, in a public offering. All of the securities to be sold in the offering are to be offered by Athersys. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Oct 25, 2022 08:30 am ET
Athersys to Host Third Quarter Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will be hosting a conference call on Thursday, November 10, 2022, at 4:30 PM Eastern Time to review its third quarter 2022 financial results.
Oct 04, 2022 09:25 am ET
Athersys to Present at 2022 Cell & Gene Meeting on the Mesa Conference and Attend 14th World Stroke Congress in October
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today their participation in two October conferences, the 2022 Cell & Gene Meeting on the Mesa on October 11-13, 2022 and the 14th World Stroke Congress on October 26-29, 2022.
Sep 30, 2022 12:33 pm ET
Athersys to Host Business Update Conference Call on October 6th
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on October 6, 2022 at 4:00 pm Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert “Willie” Mays, Executive Vice President Regenerative Medicine and Head of Neuroscience, will provide an overview of the company’s accomplishments since its recently announced restructuring.
Sep 23, 2022 09:19 am ET
Athersys Amends Securities Purchase Agreement in Connection with Recent Registered Direct Offering
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it has entered into amended agreements to extend the exercise period of the warrants that were issued as part of a registered direct offering that closed on August 17, 2022, among other changes, and to issue additional warrants to the same warrant holder, a healthcare-focused U.S. institutional investor.
Aug 26, 2022 11:05 am ET
Thinking about buying stock in Newage, Bed Bath & Beyond, Baudax Bio, Athersys, or Bilibili?
NEW YORK, Aug. 26, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NBEV, BBBY, BXRX, ATHX, and BILI.
Aug 25, 2022 04:30 pm ET
Athersys Announces 1-for-25 Reverse Stock Split
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it will be executing a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25 after the close of trading on the Nasdaq Stock Market on Friday, August 26, 2022. Athersys common stock will begin trading on a split-adjusted basis when the market opens on Monday, August 29, 2022 under the existing trading symbol “ATHX” and a new CUSIP number. The reverse stock split was previously approved by Athersys stockholders at
Aug 25, 2022 10:45 am ET
Thinking about buying stock in Bright Minds Biosciences, Kiora Pharmaceuticals, FuelCell Energy, Athersys, or Minerva Neurosciences?
NEW YORK, Aug. 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DRUG, KPRX, FCEL, ATHX, and NERV.
Aug 17, 2022 04:30 pm ET
Athersys, Inc. Announces Closing of $12 Million Registered Direct Offering
Athersys, Inc. (Nasdaq: ATHX) today announced the closing of its previously announced registered direct offering with a single healthcare-focused U.S. institutional investor for the purchase of 48,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 48,000,000 shares of common stock at a combined purchase price of $0.25, resulting in gross proceeds of approximately $12 million before deducting placement agent fees and other offering expenses. The warrants have an exercise price of $0.2554 per share and are exercisable for a f
Aug 15, 2022 08:30 am ET
Athersys, Inc. Announces $12 Million Registered Direct Offering
Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor for the purchase and sale of 48,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 48,000,000 shares of common stock at a purchase price per share (and accompanying warrant) of $0.25 in a registered direct offering. The warrants will have an exercise price of $0.2554 per share, will be initially exercisable beginning six months following the date of issuance and will expi
Aug 11, 2022 04:17 pm ET
Athersys Reports Second Quarter 2022 Financial Results and Provides Business Update
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a business update.
Aug 08, 2022 09:39 am ET
Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Across
Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory under the leadership of the Uniformed Services University of the Health Sciences, that showed intravenous MultiStem® (invimestrocel) administration provided benefit in an animal model of acute radiation syndrome (ARS). The results demonstrate that the administration of MultiStem cells increased survival in treated animals compared to vehicle treatment (p=0.03), resulted in higher b
Aug 04, 2022 08:00 am ET
Athersys Appoints Kasey Rosado as Interim Chief Financial Officer
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces today its engagement with Ankura Consulting Group, LLC and the appointment of Kasey Rosado as the Company’s interim Chief Financial Officer. Ms. Rosado joins the Company subsequent to its recent restructuring and will support management on all aspects of the Company’s financial strategy.
Aug 01, 2022 11:31 am ET
Thinking about buying stock in Nio, Advanced Micro Devices, Romeo Power, Athersys, or Li Auto?
NEW YORK, Aug. 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, AMD, RMO, ATHX, and LI.
Jul 29, 2022 10:45 am ET
Thinking about buying stock in Athersys, Geovax Labs, NRX Pharmaceuticals, Marathon Digital, or Trade Desk?
NEW YORK, July 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATHX, GOVX, NRXP, MARA, and TTD.
Jul 28, 2022 10:50 am ET
Thinking about buying stock in Athersys, Missfresh, Carnival Corp, Tilray, or Tonix Pharmaceuticals?
NEW YORK, July 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATHX, MF, CCL, TLRY, and TNXP.
Jul 26, 2022 10:00 am ET
Athersys to Host Second Quarter Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2022 financial results at approximately 4:00 PM Eastern Time on Thursday, August 11, 2022, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results.
Jul 08, 2022 07:30 am ET
Athersys and Aspire Capital Fund Terminate Relationship
Athersys, Inc. (Nasdaq: ATHX) today announced that its equity purchase agreement with Aspire Capital Fund LLC (Aspire Capital) has been terminated. The Company continues to evaluate alternative financing options to support continuing operations. After several discussions with Aspire Capital, Athersys received notice on July 6, 2022 of termination of the equity purchase agreement, effective immediately. The equity purchase agreement had been in place since May 12, 2022.
Jun 21, 2022 06:00 am ET
Athersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and Director Departures
Athersys, Inc. (Nasdaq: ATHX) today announced the Company’s slate of director candidates for its 2022 Annual Meeting of Stockholders being held on Thursday, July 28, 2022, at 8:30 a.m. ET. As previously announced, in connection with the Company’s cost-cutting and restructuring initiatives, the Board of Directors approved reducing its size from ten to five members on June 6, 2022, effective as of the Annual Meeting on July 28, 2022. In order to accelerate the implementation of this change, on June 16, 2022 the Board requested and received resignations from the following Directors: John J. Harri
Jun 17, 2022 09:31 am ET
Thinking about buying stock in Mereo BioPharma, Athersys, Nio, Bilibili, or Xpeng?
NEW YORK, June 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MREO, ATHX, NIO, BILI, and XPEV.
Jun 09, 2022 10:50 am ET
Thinking about buying stock in DiDi Global, Rigel Pharmaceuticals, Annaly Capital Management, FuelCell Energy, or Athersys?
NEW YORK, June 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DIDI, RIGL, NLY, FCEL, and ATHX.
Jun 09, 2022 07:00 am ET
Athersys Postpones Annual Meeting of Stockholders
Athersys, Inc. (Nasdaq: ATHX) today announced the postponement of its Annual Meeting of Stockholders, initially scheduled for Wednesday, June 15, 2022, at 8:30 a.m. ET. The Annual Meeting is now scheduled for Thursday, July 28, 2022, at 8:30 a.m. ET. The Annual Meeting will still be completely virtual. The record date for the meeting has changed to June 9, 2022.
Jun 08, 2022 02:45 pm ET
Athersys Hosting KOL Panel Event to Discuss TREASURE Data
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a panel discussion with leading neurology experts on Tuesday, June 14th at 5:00 p.m. ET. The event will feature four key opinion leaders (KOLs) in the field of stroke and a statistician to share their perspectives on the topline data from the TREASURE study conducted by the Company’s partner HEALIOS K.K. (Healios). The TREASURE study is a randomized, double-blind placebo-controlled study evaluating MultiStem admin
Jun 02, 2022 04:05 pm ET
Athersys Announces Restructuring and Management Changes to Focus on Its Existing Clinical Programs
Athersys, Inc. (Nasdaq: ATHX) today announced a corporate restructuring plan to reduce costs and prioritize its lead clinical programs. In connection with the restructuring, the Company is reducing its workforce up to 70%, with the majority of the reduction expected to be completed by the end of June 2022. Reducing the workforce is an initial step the Company is taking to reduce its cost structure and become more attractive to both financial and strategic partners.
May 20, 2022 10:50 am ET
Thinking about buying stock in Roblox Corp, Athersys, Plug Power, DiDi Global, or Zynga?
NEW YORK, May 20, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RBLX, ATHX, PLUG, DIDI, and ZNGA.
May 20, 2022 03:00 am ET
Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE Multistem Ischemic Stroke Study
Athersys, Inc. (Nasdaq: ATHX) announced today that its partner, HEALIOS K.K. (Healios), has reported topline results for its Japan ischemic stroke study, TREASURE. The randomized, double-blind placebo-controlled study included patients with moderate to moderate-severe ischemic stroke (baseline NIHSS 8-20) with administration of a single dose of MultiStem® cells (invimestrocel) or placebo by intravenous infusion within 18-36 hours of the event. The trial enrolled 206 patients and was conducted by 48 sites in Japan.
May 13, 2022 08:00 am ET
Athersys to Participate in the H.C. Wainwright Global Investment Conference
Athersys, Inc. (Nasdaq: ATHX), announced today that Dan Camardo, Chief Executive Officer, will participate virtually in the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, Florida. The Company’s management team will also participate in one-on-one meetings with institutional investors during the conference.
May 06, 2022 08:00 am ET
Athersys Reports First Quarter 2022 Results
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2022. In anticipation of the announcement in May of topline data from Athersys’ partner, HEALIOS K.K. (Healios), for its Phase 2/3 TREASURE study evaluating MultiStem® (invimestrocel, HLCM051) for the treatment of ischemic stroke, Athersys will host its next investor conference call after the data are released. Athersys will share the conference call details in its news release reporting the data.
May 02, 2022 09:00 am ET
Athersys to Participate in the Bank of America Securities 2022 Global Healthcare Conference
Athersys, Inc. (Nasdaq: ATHX), announced today that Dan Camardo, Chief Executive Officer, and Ivor Macleod, Chief Financial Officer, will participate in a fireside chat at the Bank of America Securities 2022 Global Healthcare Conference on Wednesday, May 11, 2022 at 4:00 p.m. PT in Las Vegas. The Company’s management team will also participate in one-on-one meetings with institutional investors during the conference.
Apr 29, 2022 09:00 am ET
Athersys to Announce First Quarter Financial Results on May 6
Athersys, Inc. (Nasdaq: ATHX) today announced that it will release its first quarter 2022 financial results on Friday, May 6, 2022, at 8:00 a.m. EDT. In anticipation of the announcement of topline data from Athersys’ partner, HEALIOS K.K., for its Phase 2/3 TREASURE study evaluating MultiStem® (invimestrocel, HLCM051) for the treatment of ischemic stroke in May, Athersys will host its next investor conference call after the data are released. Athersys will share the call details in its own news release reporting the data.
Apr 12, 2022 09:31 am ET
Thinking about buying stock in Verastem, AT&T, Athersys, Beyond Meat, or Amarin?
NEW YORK, April 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VSTM, T, ATHX, BYND, and AMRN.
Apr 04, 2022 06:00 am ET
Athersys Reports That Its Partner, HEALIOS K.K., Provides Updates on MultiStem® Clinical Programs in Japan
Athersys, Inc. (Nasdaq: ATHX) announced today that its partner, HEALIOS K.K. (Healios), has provided updates on its two clinical programs evaluating MultiStem® (invimestrocel, HLCM051) cell therapy, for which Healios has a license and is responsible for the development and commercialization of MultiStem for ischemic stroke and acute respiratory distress syndrome (ARDS) in Japan on an exclusive basis.
Apr 01, 2022 04:46 pm ET
Athersys to Participate in Two Upcoming Investor Conferences
Athersys, Inc. (Nasdaq: ATHX) announced today that William (B.J.) Lehmann, President and Chief Operating Officer, will present a corporate overview at the virtual Locust Walk Stem Cell Conference on Monday, April 11, 2022 at 2:00 p.m. ET. Mr. Lehmann will discuss the Company’s investigational clinical product platform, MultiStem® (invimestrocel) cell therapy, which is in late-stage clinical development in the areas of ischemic stroke, acute respiratory distress syndrome (ARDS) and trauma.
Mar 15, 2022 04:05 pm ET
Athersys Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
Athersys, Inc. (Nasdaq: ATHX) announced today its financial results for the three months and full year ended December 31, 2021, along with a corporate update.
Feb 17, 2022 04:30 pm ET
Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Athersys, Inc. (“Athersys” or the “Company”) (NASDAQ: ATHX) announced today that, as previously disclosed in its Form 8-K filed with the Securities and Exchange Commission on January 21, 2022, the Company made an inducement grant to Daniel Camardo, the newly-appointed Chief Executive Officer of Athersys. The Company’s Board of Directors approved, pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market Listing Rules, the grant of an inducement equity award in the form of a nonqualified stock option to purchase 10,000,000 shares of the Company’s common stock. The option was granted outside of the
Feb 15, 2022 08:00 am ET
Athersys to Host Year-End 2021 Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will release its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022, after the close of the U.S. financial markets. Athersys’ new CEO, Daniel A. Camardo, along with the Company’s management team, will host a conference call at 4:30 p.m. Eastern Time that day to review the results. Mr. Camardo joined the company as CEO on February 14, 2022. Mr. Camardo comes to Athersys at a pivotal time to lead the Company’s transition to a commercial biopharmaceutical company and leader in cell therapy. Dan has over 25 years of commercial leadership ex
Jan 26, 2022 08:00 am ET
Athersys to Host a Virtual Presentation on Its MultiStem® Programs
Athersys, Inc. (Nasdaq: ATHX), an international, clinical late-stage regenerative medicine company developing MultiStem® (invimestrocel) cell therapy, announced today that it will host a virtual investor presentation titled “MultiStem Clinical Programs: An In-Depth Look” on Wednesday, February 2, 2022, at 10:00 a.m. EST.
Jan 20, 2022 06:00 pm ET
Athersys Appoints Experienced Commercial Leader, Daniel A. Camardo, to Chief Executive Officer
Athersys, Inc. (Nasdaq: ATHX), an international, late-stage, regenerative medicine company, announced today the appointment of Daniel A. Camardo as the Company's Chief Executive Officer, effective February 14, 2022. Mr. Camardo is a senior pharmaceutical and biotech executive with more than 25 years of commercial leadership experience. As Chief Executive Officer, he will lead Athersys forward to complete the development, approval, launch, and commercialization of the Company’s MultiStem® (invimestrocel) cell therapy for the treatment of serious conditions, including ischemic stroke.
Nov 30, 2021 07:30 am ET
Thinking about buying stock in Adagio Therapeutics, Pioneer Power Solutions, ImmunoGen, Athersys, or First Wave BioPharma?
NEW YORK, Nov. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADGI, PPSI, IMGN, ATHX, and FWBI.
Nov 30, 2021 06:00 am ET
Report of Placebo-Controlled Clinical Trial Evaluating MultiStem® Cell Therapy for Acute Respiratory Distress Syndrome Published in Intensive Care Medicine
Athersys, Inc. (NASDAQ: ATHX) announced today that a manuscript reporting data from the Company’s MUST-ARDS clinical trial have been published in the peer-reviewed journal Intensive Care Medicine. MUST-ARDS was a randomized, double-blind placebo-controlled Phase 1/2 trial evaluating the safety and efficacy of MultiStem® (invimestrocel) cell therapy in patients with acute respiratory distress syndrome (ARDS). Enrolling patients at 12 intensive care units in the United Kingdom and the U.S., the study confirmed that intravenous administration of MultiStem cell therapy was well-t
Nov 15, 2021 04:05 pm ET
Athersys Reports Third Quarter 2021 Results and Provides Corporate Update
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended September 30, 2021 and provided a corporate update.
Nov 12, 2021 06:00 am ET
Athersys Reports Updates on Timing for Japan ARDS and Stroke Programs From Healios K.K.
Athersys reports that HEALIOS K.K. (Healios), its development and commercial partner in Japan, provided an update earlier this morning regarding its clinical programs for acute respiratory distress syndrome (ARDS) and ischemic stroke involving MultiStem® (HLCM051, invimestrocel) in its FY2021 Q3 financial results presentation.
Oct 18, 2021 10:07 am ET
Athersys to Host Third Quarter Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2021 financial results at approximately 4:00 PM Eastern Time on Monday, November 15, 2021, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results.
Sep 28, 2021 07:00 am ET
Athersys to Present at 2021 Cell & Gene Meeting on the Mesa Hybrid Conference
Athersys, Inc. (NASDAQ: ATHX) announced today that Dr. Robert W. Mays and Mr. William (B.J.) Lehmann will participate in person at the annual Cell & Gene Meeting on the Mesa Hybrid Conference to be held October 12th – 14th in Carlsbad, California.
Aug 10, 2021 09:17 am ET
Athersys Partner HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment for Ischemic Stroke
Athersys, Inc. (NASDAQ: ATHX) announced today that its partner, HEALIOS K.K. (“Healios”), has completed enrollment in its TREASURE study in Japan, evaluating MultiStem® (invimestrocel) cell therapy treatment in patients who have suffered an ischemic stroke. The details are provided in Healios’ press release:
Aug 09, 2021 04:05 pm ET
Athersys Reports Second Quarter 2021 Results
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended June 30, 2021 and provided a corporate update.
Aug 06, 2021 08:30 am ET
Thinking about buying stock in Westport Fuel Systems, Switch, Athersys, Nabriva Therapeutics, or Aurinia Pharmaceuticals?
NEW YORK, Aug. 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WPRT, SWCH, ATHX, NBRV, and AUPH.
Aug 06, 2021 06:00 am ET
Athersys Partner HEALIOS K.K. Announces Positive Topline Results of MultiStem for Acute Respiratory Distress Syndrome in the ONE-BRIDGE Study
Athersys, Inc. (NASDAQ: ATHX) announced today that its partner in Japan, HEALIOS K.K. (Healios), has released positive topline data from its ONE-BRIDGE clinical trial evaluating the safety and efficacy of MultiStem® cell therapy (invimestrocel) in patients with acute respiratory distress syndrome (ARDS). The details are provided in Healios’ press release:
Aug 05, 2021 05:57 pm ET
Athersys and HEALIOS K.K. Announce Advancement of Their MultiStem Commercial Partnership
Athersys, Inc. (NASDAQ: ATHX) and HEALIOS K.K. (Healios) (TSE Mothers: 4593) jointly announced today an expansion and deepening of their partnership to optimize and better align the collaboration structure to drive therapeutic reach and commercial success in Japan for the MultiStem® (invimestrocel) product following potential regulatory approval. The changes and new agreements reflect improved clarity regarding Japanese regulatory, manufacturing, and commercial requirements gained in recent years and better enable the optimal investments and efforts in manufacturing and commercializ
Aug 05, 2021 04:36 pm ET
Athersys and Healios K.K. Announce Advancement of Their MultiStem Commercial Partnership
Athersys, Inc. (NASDAQ: ATHX) and HEALIOS K.K. (Healios) (TSE Mothers: 4593) jointly announced today an expansion and deepening of their partnership to optimize and better align the collaboration structure to drive therapeutic reach and commercial success in Japan for the MultiStem® (invimestrocel) product following potential regulatory approval. The changes and new agreements reflect improved clarity regarding Japanese regulatory, manufacturing, and commercial requirements gained in recent years and better enable the optimal investments and efforts in manufacturing and commercializ
Jul 13, 2021 10:30 am ET
Athersys to Host Second Quarter Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2021 financial results at approximately 4:00 PM Eastern Time on Monday, August 9, 2021, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results.
Jun 30, 2021 06:00 am ET
New Publication Provides Further Clarity of MultiStem's Mechanism of Action on Modulating the Inflammatory Response in Critical Care Indications
Athersys, Inc. (NASDAQ: ATHX) announced today that data accumulated from several years of preclinical research was published in the peer-reviewed journal Scientific Reports. The publication describes the findings from extensive in vitro studies investigating the role Multipotent Adult Progenitor Cells (MAPC®), clinically known as MultiStem® (invimestrocel), have in modulating the inflammatory response. The report provides evidence of potential mechanisms by which MAPC cells promote regulatory T cell (Treg) differentiation and proliferation and
May 06, 2021 04:05 pm ET
Athersys Reports First Quarter 2021 Results
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2021 and provided a corporate update.
Apr 28, 2021 01:00 pm ET
Athersys to Present at the Bank of America Virtual Healthcare Conference on May 12
Ivor Macleod, Chief Financial Officer of Athersys Inc. (NASDAQ: ATHX), is scheduled to speak at the Bank of America Securities 2021 Virtual Health Care Conference on Wednesday, May 12, 2021 at 12:30 pm EDT. Following a brief corporate update, Mr. Macleod will engage in a Q & A fireside chat with a Bank of America analyst. The Company will also engage in virtual meetings with other institutional representatives at the conference.
Apr 13, 2021 07:00 am ET
Athersys to Host First Quarter Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will release its first quarter 2021 financial results at approximately 4:00 PM Eastern Time on Thursday, May 6, 2021, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results.
Apr 01, 2021 07:00 am ET
Athersys to Present at the Needham Virtual Healthcare Conference on April 14
Athersys, Inc. (NASDAQ: ATHX) announced today that Mr. Ivor Macleod, Chief Financial Officer, will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference. The presentation is scheduled for Wednesday, April 14, 2021 at 1:30 pm EDT. The company will also engage in virtual meetings with other institutional representatives at the conference.
Mar 31, 2021 06:00 am ET
Athersys Reports That Healios Has Completed Enrollment in the ONE-BRIDGE Study of MultiStem® for Acute Respiratory Distress Syndrome in Japan
Athersys, Inc. (Nasdaq: ATHX) announced today that its partner HEALIOS K.K. (Healios) has completed enrollment in the ONE-BRIDGE study in Japan evaluating MultiStem® (invimestrocel) in patients with acute respiratory distress syndrome (ARDS) caused by pneumonia.
Mar 25, 2021 04:05 pm ET
Athersys Announces Financial Results for Fourth Quarter and Full Year 2020
Athersys, Inc. (NASDAQ: ATHX) announced today its fourth quarter 2020 and annual 2020 financial results and recent highlights.
Mar 02, 2021 07:00 am ET
Athersys to Host Year-End 2020 Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will release its year-end 2020 financial results at approximately 4:00 PM Eastern Time on Thursday, March 25, 2021, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results.
Feb 16, 2021 07:50 am ET
Athersys Announces Cooperation Agreement With HEALIOS K.K.
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® cell therapy, today announced that it has entered into a cooperation agreement with HEALIOS K.K. (“Healios”), the Company’s largest shareholder and one of its commercial partners, and Dr. Hardy TS Kagimoto, a member of the Company’s Board and the Chairman and Chief Executive Officer of Healios. The cooperation agreement is intended to reaffirm the mutual commitment to collaborative development of MultiStem in Japan.
Feb 16, 2021 07:00 am ET
Athersys Announces CEO Transition
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® cell therapy, today announced that Dr. Gil Van Bokkelen has stepped down as Chairman and Chief Executive Officer, effective immediately. The Athersys Board has appointed William (B.J.) Lehmann, the Company’s President and Chief Operating Officer, as Interim Chief Executive Officer. Dr. Ismail Kola, Lead Director of the Athersys Board, has been appointed Chairman of the Board.
Jan 28, 2021 06:00 am ET
Athersys to Host a Virtual Investor Day
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® cell therapy, announced today that the Company will host a virtual investor day on Tuesday, February 16, 2021, beginning at 11:00 AM EST.
Dec 21, 2020 06:00 am ET
UTHealth in Houston and Athersys Announce Commencement of Patient Enrollment in a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma
The University of Texas Health Science Center at Houston (UTHealth) and Athersys, Inc. (NASDAQ: ATHX) announced today that the first patient has been enrolled in a clinical study evaluating MultiStem® cell therapy for the potential early treatment of traumatic injuries and the subsequent complications that result. The MATRICS-1 (MultiStem Administration for Trauma Related Inflammation and Complications) study is being conducted at Memorial Hermann-Texas Medical Center, one of the busiest Level 1 trauma centers in the United States.
Nov 16, 2020 06:00 am ET
Athersys Announces Three Appointments to Board of Directors
Athersys, Inc. (NASDAQ: ATHX), a clinical-stage regenerative medicine company, is pleased to announce that it has appointed Ms. Katherine Kalin, Ms. Jane Wasman and Mr. Baiju R. Shah to its board of directors. Each of these senior executives possess significant healthcare experience and are strategic leaders in the industry. This prestigious group of professionals will help lead the Company as it prepares for potential commercialization of its investigational cell therapy, MultiStem®. In addition, Dr. Lee Babiss, a committed director since 2010, has announced his re
Nov 09, 2020 04:05 pm ET
Athersys Reports Third Quarter 2020 Results and Provides Corporate Update
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended September 30, 2020 and provided a corporate update.
Oct 08, 2020 01:17 pm ET
Athersys to Host Third Quarter Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2020 financial results at approximately 4:00 PM Eastern Time on Monday, November 9, 2020, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Members of the management team will host the call as follows:
Sep 23, 2020 06:00 am ET
FDA Grants RMAT Designation to MultiStem Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome
Athersys, Inc., a leading regenerative medicine company in late-stage clinical development, announced today that MultiStem® cell therapy was granted Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the acute respiratory distress syndrome (ARDS) program. The RMAT designation enables sponsors to work closely with the FDA and receive their guidance on expediting development of their products, including providing advice on generating the evidence needed to support approval in an efficient manner. RMAT designation invites the
Aug 10, 2020 04:00 pm ET
Athersys Reports Second Quarter 2020 Results
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended June 30, 2020.
Jul 20, 2020 02:00 pm ET
Athersys to Host Second Quarter Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2020 financial results at approximately 4:00 PM Eastern Time on Monday, August 10, 2020, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Members of the management team will host the call as follows:
Jun 22, 2020 10:35 am ET
Thinking about buying stock in SINTX Technologies, China Automotive Systems, Athersys Inc, Theratechnologies, or Biocept Inc?
NEW YORK, June 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SINT, CAAS, ATHX, THTX, and BIOC.
May 18, 2020 06:00 am ET
Athersys Announces Upcoming Presentations at the International Society of Cell and Gene Therapy Virtual Conference
Athersys, Inc. (NASDAQ: ATHX) announced today its participation in several sessions at this year’s International Society for Cell and Gene Therapy (ISCT) virtual conference taking place May 28 – 29, 2020. ISCT 2020 is the largest global translation-focused cell and gene therapy (CGT) meeting and is expected to draw delegates from more than 50 countries in the virtual event. Dr. Anthony Ting, Vice President of Regenerative Medicine and Head of Cardiopulmonary Programs and co-chair for the Strategies for Commercialization track at the ISCT 2020 virtual conference, will take an active role in thr
May 07, 2020 04:05 pm ET
Athersys Reports First Quarter 2020 Results
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2020.
May 05, 2020 06:00 am ET
Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study, a Pivotal Phase 2/3 Trial Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS
Athersys, Inc. (NASDAQ: ATHX) announced today that the first patients have been enrolled in Athersys’ pivotal Phase 2/3 study entitled, MultiStem® Administration for COVID-19 Induced Acute Respiratory Distress Syndrome (MACOVIA). The patients were enrolled at University Hospital’s Cleveland Medical Center (UH Cleveland), a leading pulmonary critical care center and a nationally ranked hospital. Medpace, a leading contract research organization (CRO) based in Cincinnati, Ohio, is serving as the CRO for this study.
May 01, 2020 06:00 am ET
Athersys and University Hospitals Cleveland Medical Center Announce Activation of the First Clinical Site for the MACOVIA Study, a Pivotal Phase 2/3 Study Evaluating MultiStem® Cell Therapy for COVID-
Athersys, Inc. (NASDAQ: ATHX) and University Hospitals Cleveland Medical Center (UH Cleveland) announced today that UH Cleveland is now open as the first clinical site for the MACOVIA (MultiStem® Administration for COVID-19 Induced Acute Respiratory Distress Syndrome) trial.
Apr 29, 2020 02:47 pm ET
Athersys to Present at the Bank of America Merrill Lynch Virtual Healthcare Conference on May 14
Athersys, Inc. (NASDAQ: ATHX) announced today that Gil Van Bokkelen, Chairman and CEO, will present a corporate overview at the Bank of America Merrill Lynch 2020 Virtual Healthcare Conference to investors and analysts. The presentation is scheduled for Thursday, May 14, 2020 at 8:20 a.m. EDT.
Apr 21, 2020 08:00 am ET
Athersys to Host First Quarter Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will release its first quarter 2020 financial results at approximately 4:00 PM Eastern Time on Thursday, May 7, 2020, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Members of the management team will host the call as follows:
Apr 20, 2020 04:05 pm ET
Athersys Announces Closing of Public Offering of Common Stock
Athersys, Inc. (NASDAQ: ATHX) (Athersys) today announced the closing of its previously announced underwritten public offering of 25,587,500 shares of its common stock, par value $0.001 per share (Common Stock), at a price to the public of $2.25 per share, which includes 3,337,500 shares of Common Stock pursuant to the underwriters’ option to purchase additional shares, which the underwriters exercised in full on April 16, 2020. Gross proceeds to Athersys from the offering are approximately $57.6 million, before deducting the underwriting discount and estimated offering expenses.
Apr 15, 2020 09:33 pm ET
Athersys Announces Pricing of Public Offering of Common Stock
Athersys, Inc. (NASDAQ: ATHX) (Athersys) today announced the pricing of its previously announced underwritten public offering of its common stock, par value $0.001 per share (Common Stock), at a price to the public of $2.25 per share, for a total of 22,250,000 shares. Gross proceeds to Athersys from the offering are expected to be approximately $50.1 million, before deducting the underwriting discount and estimated offering expenses. In connection with the offering, Athersys has granted the underwriters a 30-day option to purchase up to an additional 3,337,500 shares of Co
Apr 15, 2020 04:27 pm ET
Athersys Announces Proposed Public Offering of Common Stock
Athersys, Inc. (NASDAQ: ATHX) (Athersys) announced today that it intends to offer for sale $50 million of shares of its common stock, par value $0.001 per share (Common Stock), in an underwritten public offering. In addition, Athersys expects to grant the underwriters a 30-day option to purchase additional shares of Common Stock in an amount of up to 15% of the number of shares of Common Stock offered in the public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the of
Apr 15, 2020 11:47 am ET
FDA Authorizes Initiation of a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma Patients
Athersys, Inc. (NASDAQ: ATHX) announced today that the U.S. Food and Drug Administration (FDA) has authorized an Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating Athersys’ MultiStem® cell therapy for early treatment of traumatic injuries and the subsequent complications that result following severe trauma. The trial will be conducted by The University of Texas Health Science Center at Houston (UTHealth) at Memorial Hermann-Texas Medical Center in Houston, Texas, one of the busiest Level 1 trauma centers in the United States. The study repres
Apr 15, 2020 06:59 am ET
FDA Authorizes Initiation of a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma Patients
Athersys, Inc. (NASDAQ: ATHX) announced today that the U.S. Food and Drug Administration (FDA) has authorized an Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating Athersys’ MultiStem® cell therapy for early treatment of traumatic injuries and the subsequent complications that result following severe trauma. Memorial Hermann-Texas Medical Center in Houston, Texas, one of the busiest Level 1 trauma centers in the United States, intends to conduct the trial. The study represents another important application of the company’s MultiStem cell thera
Apr 15, 2020 06:00 am ET
FDA Authorizes Initiation of a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma Patients
Athersys, Inc. (NASDAQ: ATHX) announced today that the U.S. Food and Drug Administration (FDA) has authorized an Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating Athersys’ MultiStem® cell therapy for early treatment of traumatic injuries and the subsequent complications that result following severe trauma. Memorial Hermann-Texas Medical Center in Houston, Texas, one of the busiest Level 1 trauma centers in the United States, intends to conduct the trial. The study represents another important application of the company’s MultiStem cell thera
Apr 13, 2020 06:00 am ET
FDA Authorizes Athersys to Initiate a Pivotal Clinical Trial Evaluating MultiStem® Cell Therapy in Patients With COVID-19 Induced Acute Respiratory Distress Syndrome
Athersys, Inc. (NASDAQ: ATHX) announced today that the U.S. Food and Drug Administration (FDA) has authorized the Company to initiate a Phase 2/3 pivotal study to assess the safety and efficacy of MultiStem® therapy in subjects with moderate to severe acute respiratory distress syndrome (ARDS) induced by the novel coronavirus disease (COVID-19). This program falls under the current Investigational New Drug (IND) application for the Company’s completed MUST-ARDS study and, therefore, a new IND does not need to be filed. The Company plans to open the first clinical sites for recruitme
Mar 30, 2020 06:00 am ET
HEALIOS K.K. Increases Investment in Athersys by Fully Exercising Warrant to Acquire Additional Shares
Athersys, Inc. (“Athersys”) (NASDAQ: ATHX) announced today that its partner in Japan, HEALIOS K.K. (“Healios”), exercised in full its warrant to purchase shares of Athersys common stock. Healios purchased 4,000,000 shares at a price of $1.76 per share in accordance with the terms of the warrant, representing an additional investment of $7,040,000 in Athersys.
Mar 19, 2020 06:00 am ET
Athersys Names Maia Hansen Senior Vice President, Operations and Supply Chain
Athersys, Inc. (“Athersys” or the “Company”) (NASDAQ: ATHX) announced today the addition of Ms. Maia Hansen, an experienced leader in operations and supply chain management, to the Athersys leadership team. Ms. Hansen has been appointed Senior Vice President, Operations and Supply Chain to help establish and manage a sustainable supply chain built to enable reliable, cost-effective and best in class commercial manufacturing and product distribution capabilities to support commercial success. Ms. Hansen will have overall responsibility for supply chain strategy, related operations and capabilit
Mar 16, 2020 04:05 pm ET
Athersys Announces Financial Results for Fourth Quarter and Full Year 2019
Athersys, Inc. (NASDAQ: ATHX) announced today its fourth quarter 2019 and annual 2019 financial results and recent highlights.
Feb 10, 2020 08:00 am ET
Athersys to Host Year-End 2019 Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will release its year-end 2019 financial results at approximately 4:00 PM Eastern Time on Monday, March 16, 2020, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Members of the management team will host the call as follows:
Feb 03, 2020 06:00 am ET
Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Athersys, Inc. (“Athersys” or the “Company”) (NASDAQ: ATHX) announced today that, as previously disclosed in its Form 8-K filed with the Securities and Exchange Commission on January 16, 2020, the Company made an inducement grant to Ivor Macleod, the newly-appointed Chief Financial Officer of Athersys. The Company’s Board of Directors approved, pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market Listing Rules, the grant of an inducement equity award in the form of a nonqualified stock option to purchase 600,000 shares of the Company’s common stock. The option was granted outside of Athersys
Jan 15, 2020 06:00 am ET
Athersys Names Ivor Macleod Chief Financial Officer
Athersys, Inc. (NASDAQ: ATHX) announced today the addition of Mr. Ivor Macleod, CPA, MBA, a highly experienced pharmaceutical executive, to the Athersys leadership team. Mr. Macleod has been appointed Chief Financial Officer, effective as of...
Jan 14, 2020 06:00 am ET
Athersys Provides Update on One-Year ARDS Study Data
Athersys, Inc. (NASDAQ: ATHX) announced today the one-year follow-up summary results from its exploratory clinical study of the intravenous administration of MultiStem® cell therapy to treat patients who are suffering from acute respiratory...
Nov 14, 2019 06:00 am ET
Healios Receives Notification of Orphan Designation for Acute Respiratory Distress Syndrome Clinical Program
Athersys, Inc. (Nasdaq: ATHX) announced today that its collaborator in Japan, HEALIOS K.K. (“Healios”) received notification this week from the Pharmaceutical Affairs and Food Sanitation Council (“PAFSC”) that its acute respiratory distress...
Nov 06, 2019 04:05 pm ET
Athersys Reports Third Quarter 2019 Results
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended September 30, 2019. Highlights of the third quarter of 2019 and recent events include: Steady advancement of both MultiStem® ischemic stroke clinical...
Oct 14, 2019 01:00 pm ET
Athersys to Host Third Quarter Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, November 6, 2019, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the...
Sep 25, 2019 08:00 am ET
Athersys to Present at 2019 Cell & Gene Meeting on the Mesa
Athersys, Inc. (NASDAQ: ATHX) announced today that Dr. Gil Van Bokkelen, Chairman and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be held October 2nd -4th in Carlsbad, California. Dr. Van Bokkelen will provide a brief...
Aug 07, 2019 04:05 pm ET
Athersys Reports Second Quarter 2019 Results
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended June 30, 2019. Highlights of the second quarter of 2019 and recent events include: Received Fast Track designation from the FDA for our clinical...
Jul 08, 2019 11:00 am ET
Athersys to Host Second Quarter Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, August 7, 2019, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the...
Jun 04, 2019 06:00 am ET
Athersys to Present at Jefferies 2019 Healthcare Conference
Athersys, Inc. (NASDAQ: ATHX) announced today that Dr. Gil Van Bokkelen, Chairman and CEO, will present at the Jefferies 2019 Healthcare Conference taking place June 4-7, 2019 in New York City. Dr. Van Bokkelen’s presentation will take place at 11...
May 28, 2019 06:00 am ET
Athersys to Participate in four Events at the International Society of Cell and Gene Therapy Conference
Athersys, Inc. (NASDAQ: ATHX) announced today its participation in several sessions at this year’s International Society for Cell and Gene Therapy (ISCT) conference taking place May 29 – June 2, 2019 in Melbourne, Australia. ISCT 2019 is the...
May 20, 2019 12:15 pm ET
Athersys Presents Data From Its Acute Respiratory Distress Syndrome Clinical Trial at American Thoracic Society International Conference
Athersys, Inc. (Nasdaq: ATHX) announced additional favorable data from its exploratory Phase 1/2 acute respiratory distress syndrome (ARDS) clinical trial. Dr. Geoff Bellingan, Medical Director at University College London Hospitals, described the...
May 14, 2019 06:00 am ET
Athersys Announces Fast Track Designation From FDA for MultiStem® Program for Acute Respiratory Distress Syndrome
Athersys, Inc. (Nasdaq: ATHX) announced today that its clinical program evaluating MultiStem® cell therapy for the treatment of Acute Respiratory Distress Syndrome (“ARDS”) has received Fast Track designation from the United States Food and Drug...
May 08, 2019 04:05 pm ET
Athersys Reports First Quarter 2019 Results
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2019. Highlights of the first quarter of 2019 and recent events include: Announced positive results from our exploratory clinical study of...
Apr 23, 2019 06:00 am ET
HEALIOS K.K. Announces Enrollment of First Patient in Japan in the ONE-BRIDGE Study of MultiStem® Treatment for Acute Respiratory Distress Syndrome
Athersys, Inc. (Nasdaq: ATHX) announced today that its partner, HEALIOS K.K. (“Healios”), has enrolled the first patient in its ONE-BRIDGE study in Japan, evaluating MultiStem® cell therapy treatment of patients who suffer from acute respiratory...
Apr 15, 2019 10:00 am ET
Athersys to Host Investor Day in New York City
Athersys, Inc. (Nasdaq: ATHX) announced today that the company will host an investor day on Tuesday, May 14, 2019. The event will focus on the Company’s mission, core capabilities and technologies, as well as progress made on developing its...
Apr 10, 2019 02:00 pm ET
Athersys to Host First Quarter Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will release its first quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, May 8, 2019, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results....
Apr 01, 2019 01:00 pm ET
Athersys to Participate in Two Upcoming Healthcare Conferences
Athersys, Inc. (NASDAQ: ATHX) announced today the Company’s participation in two upcoming biotechnology and healthcare conferences. On April 4th, Athersys will be part of the William Blair 3rd Annual Late-Stage Therapeutics Conference taking place...
Mar 14, 2019 05:04 pm ET
Athersys Announces Financial Results for Fourth Quarter and Full Year 2018
Athersys, Inc. (NASDAQ: ATHX) announced today its fourth quarter 2018 and annual 2018 financial results and recent highlights. “As we have announced previously, we had a number of important accomplishments in 2018, including the initiation of our...
Feb 14, 2019 08:00 am ET
Athersys to Host Year-End 2018 Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will release its year-end 2018 financial results at approximately 4:00 PM Eastern Time on Thursday, March 14, 2019, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Gil...
Jan 23, 2019 06:00 am ET
Athersys Announces Positive Results From Its Exploratory Clinical Study of MultiStem® Cell Therapy for Treatment of Acute Respiratory Distress Syndrome (ARDS)
Athersys, Inc. (NASDAQ: ATHX) announced today summary results from its exploratory clinical study of the intravenous administration of MultiStem® cell therapy to treat patients who are suffering from acute respiratory distress syndrome (ARDS). The...
Dec 17, 2018 06:00 am ET
Healios Agrees to Make Payment to Extend Exclusive Period for Negotiating an Option for a License to Multistem® Therapy for Indications in China
Athersys, Inc. (NASDAQ: ATHX) announced today the extension of HEALIOS K.K.’s (Healios) exclusive period to negotiate an option that would allow Healios to obtain a license for the development and commercialization of MultiStem therapy for certain...
Nov 06, 2018 04:05 pm ET
Athersys Reports Third Quarter 2018 Results
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the period ended September 30, 2018. Highlights of the third quarter of 2018 and recent events include: Completed enrollment of our Phase 1/2 study evaluating MultiStem®...
Oct 29, 2018 08:45 am ET
Market Trends Toward New Normal in Crown, Athersys, CSX, Magellan Health, Spectrum Brands, and MGIC Investment — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Crown Holdings, Inc. (NYSE:CCK), Athersys, Inc. (NASDAQ:ATHX), CSX...
Oct 09, 2018 04:00 pm ET
Athersys to Host Third Quarter Financial Results Call
Athersys, Inc. (NASDAQ: ATHX) will release its third quarter 2018 financial results at approximately 4:00 p.m. Eastern Time on Tuesday, November 6th, 2018, and will host a conference call shortly thereafter at 4:30 p.m. Eastern Time to review the...
Sep 24, 2018 06:00 am ET
Athersys to Present at 2018 Cell & Gene Meeting on the Mesa
Athersys, Inc. (NASDAQ: ATHX) announced today that Gil Van Bokkelen, Chairman and CEO, will present at the annual Cell Gene Meeting on the Mesa to be held October 3rd-5th in La Jolla, California. Dr. Van Bokkelen will provide a brief overview of...
Aug 14, 2018 07:30 am ET
Recent Analysis Shows Williams Partners, GameStop, Opko Health, Athersys, CSX, and Kratos Defense & Security Solutions Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Williams Partners L.P. (NYSE:WPZ), GameStop Corp. (NYSE:GME), Opko Health,...
Aug 07, 2018 04:05 pm ET
Athersys Reports Second Quarter 2018 Results
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended June 30, 2018. Highlights of the second quarter of 2018 and recent events include: Announced the completion of an expansion of our collaboration with...
Aug 03, 2018 06:00 am ET
Athersys Makes Important Leadership Hire to Carry Out Its Manufacturing Strategy
Athersys, Inc. (NASDAQ: ATHX) announced the addition of an experienced manufacturing executive to oversee manufacturing operations and help plan for and lead the Company’s transition into commercial manufacturing of MultiStem®, the Company’s...
Jul 31, 2018 06:00 am ET
Athersys Announces Enrollment of First Patient in Masters-2 Phase 3 Study of Multistem® Treatment for Ischemic Stroke
Athersys, Inc. (NASDAQ: ATHX) announced today that the first patient has been enrolled its Phase 3 study entitled, MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (“MASTERS-2”) to evaluate MultiStem® cell therapy...
Jul 10, 2018 04:00 pm ET
Athersys to Host Second Quarter Financial Results Call
Athersys, Inc. (NASDAQ:ATHX) will release its second quarter 2018 financial results at approximately 4:00 PM Eastern Time on Tuesday, August 7th, 2018, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the...
Jun 07, 2018 06:00 am ET
Athersys Announces Expansion of Collaboration With Healios
Athersys, Inc. (NASDAQ:ATHX) announced today that it has entered into an agreement with HEALIOS K.K. (“Healios”) to expand their collaboration into additional therapeutic areas. Under the terms of the agreements, Healios obtained exclusive licenses...
May 10, 2018 04:03 pm ET
Athersys Reports First Quarter 2018 Results
Athersys, Inc. (NASDAQ:ATHX) announced today its financial results for the three months ended March 31, 2018. Highlights of the first quarter of 2018 and recent events include: Completed a $21.1 million equity investment and announced plans to...
May 01, 2018 06:00 am ET
Athersys and Healios Extend by One Month the Period to Complete Collaboration Expansion Agreements
CLEVELAND and TOKYO, May 01, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) and HEALIOS K.K. (“Healios”) (TSE Mothers Code:4593) have agreed to extend the period from April 30, 2018 to May 31, 2018 to complete their planned collaboration...
Apr 27, 2018 09:45 am ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Delaware Law by the Board of Athersys, Inc. -- ATHX
Levi & Korsinsky announces it has commenced an investigation of
Athersys, Inc. (NASDAQCM: ATHX) concerning possible breaches of
Delaware law by the board of directors of the company. To obtain
additional information, go to:
Apr 25, 2018 07:50 am ET
Recent Analysis Shows First Cash, ADTRAN, OMNOVA Solutions, Athersys, Oppenheimer, and Conn's Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, April 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of First Cash, Inc. (NYSE:FCFS), ADTRAN, Inc....
Apr 23, 2018 06:00 am ET
UTHealth in Houston and Athersys Announce Funding for Clinical Trial using MultiStem® to Treat Trauma Patients
Pioneering Phase 2 study of cell therapy in Trauma to be conducted at major Level 1 Trauma Center in the U.S. with funding from MTEC Grant Award
Apr 12, 2018 04:00 pm ET
Athersys to Host First Quarter Financial Results Call
CLEVELAND, April 12, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) will release its first quarter 2018 financial results at approximately 4:00 PM Eastern Time on Thursday, May 10, 2018, and will host a conference call shortly thereafter at...
Mar 20, 2018 01:00 pm ET
Athersys to Present at Needham Healthcare Conference on March 28
CLEVELAND, March 20, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) announced today that Gil Van Bokkelen, Chairman and CEO, will present a corporate overview at the 17th Annual Needham Healthcare Conference at The Westin Grand Central Hotel in...
Mar 13, 2018 04:05 pm ET
Athersys Reports Financial Results for Fourth Quarter, Full Year 2017
Company also announces equity investment and binding letter of intent to expand HEALIOS K.K. collaboration, covered in a separate release
Mar 13, 2018 06:00 am ET
Athersys and HEALIOS Announce Binding Letter of Intent to Expand MultiStem® Collaboration
Equity investment and binding letter of intent outlines expansion of Japan collaboration, including exclusive option for China development and commercialization
Mar 01, 2018 07:40 am ET
Report: Exploring Fundamental Drivers Behind BWX Technologies, WMIH, Conn's, Athersys, Proofpoint, and Kindred Healthcare — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of BWX Technologies, Inc. (NYSE:BWXT), WMIH Corp....
Feb 12, 2018 01:30 pm ET
Athersys to Host Year-End 2017 Financial Results Call
CLEVELAND, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) will release its year-end 2017 financial results at approximately 4:00 PM Eastern Time on Tuesday, March 13, 2018, and will host a conference call shortly thereafter at 4:30...
Feb 02, 2018 06:00 am ET
Athersys Enters Into New $100 Million Equity Facility with Aspire Capital
Provides access to capital to support ongoing business and development objectives
Jan 29, 2018 06:00 am ET
Athersys CEO to Speak at the 2018 Brain Health Summit
Event held in conjunction with Super Bowl LII will focus on key issues in neurological medicine and women’s brain health
Jan 04, 2018 08:15 am ET
Detailed Research: Economic Perspectives on Athersys, Repros Therapeutics, GCP Applied Technologies, IDACORP, Mobile Mini, and Corindus Vascular Robotics — What Drives Growth in Today's Competitive La
NEW YORK, Jan. 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Athersys, Inc. (NASDAQ:ATHX), Repros Therapeutics Inc....
Nov 15, 2017 10:05 am ET
HEALIOS Announces Enrollment of First Patient in Japan in TREASURE Study of MultiStem® Treatment for Ischemic Stroke
Off-the-shelf stem cell therapy has potential to extend treatment window and enhance recovery for stroke patients
Nov 08, 2017 04:03 pm ET
Athersys Reports Third Quarter 2017 Results
Management to host conference call at 4:30 pm EST today
Oct 09, 2017 10:00 am ET
Athersys to Host Third Quarter Financial Results Call
CLEVELAND, Oct. 09, 2017 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) will release its third quarter 2017 financial results at approximately 4:00 PM Eastern Time on Wednesday, November 8, 2017, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:...
Aug 09, 2017 04:05 pm ET
Athersys Reports Second Quarter 2017 Results
CLEVELAND, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the three months ended June 30, 2017....
Mar 29, 2017 04:00 pm ET
Athersys to Present at Needham Healthcare Conference on April 4
CLEVELAND, March 29, 2017 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) announced today that Gil Van Bokkelen, Chairman and CEO, will present a corporate overview at the 16th Annual Needham Healthcare Conference at The Westin New York Grand Central Hotel in New York City. The presentation is scheduled for Tuesday, April 4, 2017 at 12:10 pm ET....
Mar 09, 2017 04:05 pm ET
Athersys Reports Financial Results for Fourth Quarter, Full Year 2016
Company also announces priority review designation obtained by Healios in Japan-accelerating potential approval pathway for MultiStem® clinical program for ischemic stroke ...
Feb 23, 2017 07:00 am ET
Overview of MultiStem® Clinical Trial in Japan Presentation at International Stroke Conference 2017
CLEVELAND, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today a presentation featuring its MultiStem® cell therapy treatment for ischemic stroke at the International Stroke Conference 2017 this week in Houston. Dr. Kiyohiro Houkin, Professor and Chairman at Department of Neurosurgery of Hokkaido University Graduate School of Medicine, and Director of Hokkaido University Hospital, will present an overview of the Treatment Evaluation of Acute Stroke Using Regenerative Cell Elements (TREASURE) study, which is the Phase II/III trial of MultiStem (HLCM051) being cond...
Feb 01, 2017 04:05 pm ET
Athersys Announces Closing of Public Offering of Common Stock
CLEVELAND, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) (“Athersys”) today announced the closing of its previously announced underwritten public offering of 22,772,300 shares of its common stock, par value $0.001 per share (“Common Stock”), at a price to the public of $1.01 per share, which includes the underwriters’ full exercise of their option to purchase an additional 2,970,300 shares of Common Stock that was exercised on January 31, 2017. Gross proceeds to Athersys from the offering are approximately $23.0 million, before deducting underwriting discounts, commission...
Jan 26, 2017 04:28 pm ET
Athersys Announces Proposed Public Offering of Common Stock
CLEVELAND, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) (“Athersys”) announced today that it intends to offer for sale shares of its common stock, par value $0.001 per share (“Common Stock”), in an underwritten public offering pursuant to its effective shelf registration statement (Registration No. 333-194538) (the “Registration Statement”) previously filed with the U.S. Securities and Exchange Commission (“SEC”), and all of the shares of Common Stock offered for sale in the public offering will be sold by Athersys. William Blair & Company, L.L.C. is acting as sole b...
Nov 03, 2016 09:00 am ET
Athersys to Present at Stifel 2016 Healthcare Conference in New York
CLEVELAND, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) announced today that Gil Van Bokkelen, Chairman and CEO, will present at the Stifel 2016 Healthcare Conference at the Lotte New York Palace Hotel in New York. The presentation is scheduled for Wednesday, November 16, 2016 at 3:45 pm ET in the Garrison conference room....
Oct 11, 2016 09:00 am ET
Athersys to Host Third Quarter Financial Results Call
CLEVELAND, Oct. 11, 2016 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) will release its third quarter 2016 financial results at approximately 4:00 PM Eastern Time on Wednesday, November 9, 2016, and host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:...
Sep 28, 2016 06:30 am ET
Athersys Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Study of MultiStem® Treatment for Ischemic Stroke
CLEVELAND, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) announced today that it has received agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the design and planned analysis of a Phase 3 clinical trial of Athersys’ novel MultiStem® cell therapy product for the treatment of ischemic stroke. The SPA provides agreement from the FDA that the protocol design, clinical endpoints, planned conduct and statistical analyses encompassed in Athersys’ planned Phase 3 study are acceptable to support a regulatory submission for a...
Sep 12, 2016 06:30 am ET
Athersys Announces Acceptance by PMDA of Clinical Trial Notification in Japan for Treatment of Ischemic Stroke With MultiStem®
CLEVELAND, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today the successful completion of Japan’s Pharmaceutical and Medical Devices Agency (PMDA) review of the Clinical Trial Notification (CTN), allowing the commencement by HEALIOS K.K. (Healios) of a confirmatory clinical trial evaluating the safety and efficacy of administration of MultiStem®, Athersys’ novel cell therapy product, for the treatment of ischemic stroke in Japan (also designated by Healios as HLCM051 in Japan). In accordance with the regulatory system in Japan, a CTN is equivalent to an Inves...
Aug 09, 2016 04:03 pm ET
Athersys Reports Second Quarter 2016 Results
CLEVELAND, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the three months ended June 30, 2016....
Jul 07, 2016 11:00 am ET
Athersys to Host Second Quarter Financial Results Call
CLEVELAND, July 07, 2016 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) will release its second quarter 2016 financial results at approximately 4:00 PM Eastern Time on Tuesday, August 9, 2016, and host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:...
Jun 27, 2016 09:35 am ET
Athersys Joins Russell 3000® Index
CLEVELAND, June 27, 2016 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it has joined the broad-market Russell 3000® Index as of the conclusion of the Russell U.S. Indices annual reconstitution, which became effective after the U.S. market opened on June 27, 2016. The preliminary list of additions was posted by FTSE Russell earlier this month....
May 05, 2016 04:05 pm ET
Athersys Reports First Quarter 2016 Results
CLEVELAND, May 05, 2016 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the three months ended March 31, 2016....
Feb 11, 2016 09:00 am ET
Rodman & Renshaw's Ram Selvaraju Interviewed by The Life Sciences Report
Raghuram "Ram" Selvaraju of Rodman & Renshaw has made the micro- and small-cap biotech universe his specialty, and his track record is impressive. In this interview with The Life Sciences Report, Selvaraju, a former big pharma researcher,...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.